According to Zhitong Finance App, Xinguang Pharmaceutical (300519.SZ) released its 2023 annual performance report. During the reporting period, the company achieved operating income of 270 million yuan, a year-on-year decrease of 23.07%; net profit attributable to shareholders of listed companies was 60.3565 million yuan, a year-on-year decrease of 40.86%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 60.1236 million yuan, a year-on-year decrease of 42.72%; the company plans to distribute a cash dividend of 4.00 yuan for every 10 shares to all shareholders.
During the reporting period, the company's leading products were astragalus extract, stretzendan capsules, and American ginseng oral liquid. Among them, drinking Astragalus accounts for 76.09%; stretchantan capsules accounted for 8.48%; and American ginseng oral liquid accounted for 12.43%. The company's consolidated gross margin was 41.27%. During the reporting period, the company will continue to step up market cultivation efforts for other products and actively cultivate new growth points.
During the reporting period, according to market demand, the company continued to comprehensively improve production efficiency by integrating existing production resources, scientifically preparing production plans, and fully exploiting production potential. While ensuring product quality, the company guaranteed the market supply of leading products.